Form 4: Tandem Diabetes Care: Executive Stock Unit Grant

Jean-Claude Kyrillos, EVP & COO of Tandem Diabetes Care, received a grant of 29,136 Restricted Stock Units (RSUs) on May 29, 2026.

Summary

• Jean-Claude Kyrillos, Executive Vice President & Chief Operating Officer of Tandem Diabetes Care Inc., was granted 29,136 Restricted Stock Units (RSUs) on May 29, 2026.
• These RSUs represent a contingent right to receive either one share of common stock or cash in lieu thereof.
• The vesting schedule indicates that one-third of the RSUs will vest on May 29, 2027, with the remaining RSUs vesting in eight equal quarterly installments thereafter.
• This transaction is filed under Section 16(a) of the Securities Exchange Act of 1934, indicating changes in beneficial ownership by an insider.
• A substitute Power of Attorney was filed on May 20, 2026, appointing Jerilyn Laskie as an attorney-in-fact for various individuals, including Jean-Claude Kyrillos, to execute and file documents with the SEC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it pertains to a standard executive compensation event (RSU grant) and does not provide new financial or operational information about the company's performance.

Positives

• Grant of Restricted Stock Units (RSUs) to a key executive, indicating continued investment in management and potential alignment of interests with shareholders.
• The vesting schedule is phased, encouraging long-term commitment from the executive.
• The filing is routine for reporting insider transactions, demonstrating compliance with SEC regulations.

Negatives

• No financial performance data or operational updates are included in this specific filing, limiting the assessment of the company's current health.
• The value of the RSU grant is not disclosed in this document.

Risks

• The vesting of RSUs is subject to the terms of the 2023 Plan, implying potential forfeiture if conditions are not met.
• The filing does not provide information on the company's overall financial performance or market position, which are key risk indicators.

Future Outlook

The future outlook is not directly addressed in this filing, which focuses on a specific insider transaction. The vesting schedule for the RSUs implies a forward-looking incentive for the executive over the next several years.

Management Comments

• Each restricted stock unit (RSU) represents a contingent right to receive either one share of the Issuer's common stock or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).
• One-third of such RSUs shall vest on 5/29/2027, and the remaining RSUs shall vest in eight (8) equal quarterly installments on the 15th of the month thereafter subject to the terms of the 2023 Plan.

Industry Context

StockSavvy.ai notes that the granting of Restricted Stock Units (RSUs) to key executives is a common practice in the medical device and technology sectors, including diabetes care, to attract, retain, and incentivize top talent by aligning their financial interests with the company's long-term performance and stock value.

Stakeholder Impact

• Shareholders: The RSU grant aligns executive interests with long-term shareholder value creation, potentially leading to better company performance.
• Employees: The grant to a senior executive may reflect the company's overall compensation strategy and its focus on retaining key talent.
• Management: Jean-Claude Kyrillos benefits from a long-term incentive tied to the company's stock performance.

Next Steps

• Vesting of RSUs according to the schedule: one-third on May 29, 2027, and the remainder in eight quarterly installments thereafter.
• Continued compliance with SEC reporting requirements for insider transactions.

Key Dates

Keywords

Form 4, Insider Transaction, Restricted Stock Units, Tandem Diabetes Care, TNDM, Jean-Claude Kyrillos, Executive Compensation, SEC Filing, Beneficial Ownership